Main Article Content
Background. The importance of the problem of chronic gastritis (CG) is determined by its high proportion in the structure of gastrointestinal pathology, reduced quality of life of patients, and possible complications. The study aimed at the investigation of the incidence and features of the clinical course of CG in servicemen at the present stage and pharmacoeconomic efficacy of bismuth and triple anti-helicobacter therapy (AHBT) in H. pylori (HP) — associated erosive gastritis with the use of domestic drugs. Materials and methods. At the first stage, the indicators of the admission rate of servicemen with CG and the peculiarities of the endoscopic picture of the gastric mucosa were analyzed. At the second stage, the features of the clinical course were studied and a pharmacoeconomic analysis of treatment regimens in servicemen with HP-associated erosive gastritis with proton pump inhibitors of different generations and domestic bismuth subcitrate, used in triple and bismuth-containing regimens, was performed. Results. An epidemiological, clinical, and pharmacoeconomic analysis of HP-associated CG in servicemen at the present stage has been conducted. It is reasonable to treat servicemen with HP-associated erosive gastritis with domestic drugs using bismuth-containing anti-helicobacter therapy, which will improve the efficiency and quality of treatment and avoid unjustified budget costs. Conclusions. Among the servicemen of the Armed Forces of Ukraine, starting from 2013, there is a tendency to increase the number of erosive gastroduodenal lesions with a predominant lesion of the antrum of the stomach. Pharmacoeconomic analysis of the treatment of HP-associated erosive gastritis showed the feasibility of switching to bismuth-containing AHBT with the use of domestic rabeprazole and bismuth subcitrate. This is justified by a higher anti-Helicobacter activity by 1.2 times (20 %), 1.6 times better (60 %) cost-effectiveness, and 1.4 times higher (40 %) cost-utility.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Gerasymova OO, Ovsienko YeV. The results of VEN/frequency analysis of pharmacotherapy of patients with chronic gastroduodenitis in a healthcare institution of Kharkiv. Social pharmacy in health care. 2018;4(2):70-75. doi:10.24959/sphhcj.18.112. (in Ukrainian).
Gradov AP, Grinevich VB. Conceptual bases of definition of medico-economic efficiency of medical processes. Gedeon Richter in CIS. 2000;(3):5-9. (in Russian).
Stepanov YuM, Mosiichuk LM. The role of bismuth in the treatment of gastroduodenal pathology (literature review and own researches). Gastroenterologìa. 2016;(61):9-17. doi:10.22141/2308-2097.3.61.2016.79151. (in Ukrainian).
Stepanov YuM. Digestive diseases and gastroenterological care for the population of Ukraine: achievements, problems and solutions. Zdorov’ja Ukrai'ny. Gastroenterologija. Gepatologija. Koloproktologija. 2014;(33):10-11. (in Ukrainian).
Iakovlievа LV, Bezditko NV, Gerasymova OO, et al. Farmakoekonomika: navchal'nyj posibnyk dlja studentiv VNZ [Pharmacoeconomics: a textbook for university students]. Vinnytsya: Nova knyga; 2009. 208 р. (in Ukrainian).
Fadieienko GD, Nikiforova YaV, Cherelyuk NI. The ways of antihelicobacter therapy in Ukraine (based on the data of analysis of the Ukrainian Registry Hp-EuReg - UKRAINE). Zdorov'ja Ukrai'ny. Gastroenterologija. Gepatologija. Koloproktologija. 2018;(50):27-28. (in Ukrainian).
McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Sep;36(5):414-425. doi:10.1111/j.1365-2036.2012.05211.x.